BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 14766260)

  • 1. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.
    Look KY; Sandler A; Blessing JA; Lucci JA; Rose PG;
    Gynecol Oncol; 2004 Feb; 92(2):644-7. PubMed ID: 14766260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
    Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
    Hensley ML; Blessing JA; Mannel R; Rose PG
    Gynecol Oncol; 2008 Jun; 109(3):329-34. PubMed ID: 18534250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
    Smith HO; Blessing JA; Vaccarello L
    Gynecol Oncol; 2002 Jan; 84(1):140-4. PubMed ID: 11748990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
    Hensley ML; Maki R; Venkatraman E; Geller G; Lovegren M; Aghajanian C; Sabbatini P; Tong W; Barakat R; Spriggs DR
    J Clin Oncol; 2002 Jun; 20(12):2824-31. PubMed ID: 12065559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.
    Look KY; Blessing JA; Valea FA; McGehee R; Manetta A; Webster KD; Andersen WA
    Gynecol Oncol; 1997 Dec; 67(3):255-8. PubMed ID: 9441772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
    Von Burton G; Rankin C; Zalupski MM; Mills GM; Borden EC; Karen A
    Am J Clin Oncol; 2006 Feb; 29(1):59-61. PubMed ID: 16462504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
    Tait DL; Blessing JA; Hoffman JS; Moore KN; Spirtos NM; Lachance JA; Rotmensch J; Miller DS
    Gynecol Oncol; 2011 Apr; 121(1):118-21. PubMed ID: 21159366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
    Miller BE; Blessing JA; Stehman FB; Shahin MS; Yamada SD; Secord AA; Warshal DP; Abulafia O; Richards WE; Van Le L
    Gynecol Oncol; 2010 Aug; 118(2):139-44. PubMed ID: 20452658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
    Schilder RJ; Blessing J; Cohn DE
    Gynecol Oncol; 2005 Jan; 96(1):103-7. PubMed ID: 15589587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group.
    Schilder RJ; Blessing JA; Morgan M; Mangan CE; Rader JS
    Gynecol Oncol; 2000 Feb; 76(2):204-7. PubMed ID: 10637071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of gemcitabine in advanced sarcomas.
    Okuno S; Edmonson J; Mahoney M; Buckner JC; Frytak S; Galanis E
    Cancer; 2002 Jun; 94(12):3225-9. PubMed ID: 12115355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
    D'Agostino G; Amant F; Berteloot P; Scambia G; Vergote I
    Gynecol Oncol; 2003 Mar; 88(3):266-9. PubMed ID: 12648573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
    Takano T; Niikura H; Ito K; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Tokunaga H; Kaiho-Sakuma M; Shiga N; Nagai T; Tanaka S; Otsuki A; Kurosawa H; Shigeta S; Tsuji K; Yamaguchi T; Yaegashi N
    Int J Clin Oncol; 2014 Oct; 19(5):897-905. PubMed ID: 24149774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Rose PG; Blessing JA; Soper JT; Barter JF
    Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
    Pautier P; Floquet A; Penel N; Piperno-Neumann S; Isambert N; Rey A; Bompas E; Cioffi A; Delcambre C; Cupissol D; Collin F; Blay JY; Jimenez M; Duffaud F
    Oncologist; 2012; 17(9):1213-20. PubMed ID: 22907974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
    Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
    Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
    Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix.
    Burnett AF; Roman LD; Garcia AA; Muderspach LI; Brader KR; Morrow CP
    Gynecol Oncol; 2000 Jan; 76(1):63-6. PubMed ID: 10620443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.